75. 關於 HCC surveillance test 用於 early HCC detection，下列何者正確？(1) Ultrasound + AFP: sensitivity 約 61%，specificity 約 92%(2) AASLD recommends HCC surveillance using a combination of liverultrasound and AFP(3) GALAD: sensitivity 約 54-72%，specificity 約 90%(4) AFP-L3%: sensitivity 約 50%，specificity 約 80%(5) PIKVA-II: sensitivity 約 40%，specificity 約 81%(A) (1)＋(2)＋(3)(B) (1)＋(2)＋(3)＋(5)(C) (1)＋(2)＋(3)＋(4)(D) (1)＋(2)(E) (1)＋(2)＋(3)＋(4)＋(5)

75. 關於 HCC surveillance test 用於 early HCC detection，下列何者正確？
(1) Ultrasound + AFP: sensitivity 約 61%，specificity 約 92%
(2) AASLD recommends HCC surveillance using a combination of liver
ultrasound and AFP
(3) GALAD: sensitivity 約 54-72%，specificity 約 90%
(4) AFP-L3%: sensitivity 約 50%，specificity 約 80%
(5) PIKVA-II: sensitivity 約 40%，specificity 約 81%
(A) (1)＋(2)＋(3)
(B) (1)＋(2)＋(3)＋(5)
(C) (1)＋(2)＋(3)＋(4)
(D) (1)＋(2)

(E) (1)＋(2)＋(3)＋(4)＋(5)

答案：登入後查看
統計： A(0), B(2), C(0), D(0), E(1) #3588531

詳解 (共 1 筆)

MoAI - 您的AI助手

B1 · 2025/09/30

#6814656

1. 題目解析這道題目主要考察HCC...

(共 1002 字，隱藏中）

前往觀看

73. 依據 2023 AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma，下列何者敘述正確？(1) Patients with advanced HCC who have Child-Turcotte-Pugh A cirrhosisshould be offered atezolizumab plus bevacizumab or durvalumab plustremelimumab as preferred first-line therapy options(2) Patients with recent GI bleeding within 6 months and those with high-riskstigmata for bleeding on EGD should have varices adequately treated priorto atezolizumab plus bevacizumab initiation, or these patients may beconsidered for durvalumab plus tremelimumab(3) AASLD advises sorafenib or lenvatinib as preferred agents after first-linedurvalumab plus tremelimumab if patients are not eligible for clinical trials(4) Well-selected patients with Child-Turcotte-Pugh B cirrhosis may be offeredsorafenib, lenvatinib, or single-agent anti-PD1 or anti-PDL1 ICI therapy(A) (3)＋(4)(B) (1)＋(2)＋(4)(C) (3)(D) (1)＋(2)＋(3)(E) (1)＋(2)＋(3)＋(4)

詳解 (共 1 筆)

其他試題